T Peptide

General Information


DRACP ID  DRACP00498

Peptide Name   T Peptide

Sequence  TKPRKTKPRKTKPRKTKPR

Sequence Length  19

UniProt ID  Not available

PubChem CID  Not available

Origin  Tuftsin derivative

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Hep-G2 Hepatoblastoma; Hepatoblastoma Blastoma 69.6% maximum inhibitory rate at 8 mg/kg MTT assay 48 h 1
HT-29 Colon adenocarcinoma Carcinoma 70% maximum inhibitory rate at 8 mg/kg MTT assay 48 h 1
BGC-823 Human papillomavirus-related endocervical adenocarcinoma Carcinoma 67.2% maximum inhibitory rate at 8 mg/kg MTT assay 48 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antitumor



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00498

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C102H190N38O24

Absent amino acids  ACDEFGHILMNQSVWY

Common amino acids  K

Mass  265407

Pl  13

Basic residues  11

Acidic residues  0

Hydrophobic residues  0

Net charge  11

Boman Index  -10881

Hydrophobicity  -286.84

Aliphatic Index  0

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 24714081

Title  Anticancer activity of tuftsin-derived T peptide in postoperative residual tumors

Doi 10.1097/CAD.0000000000000111

Year  2014

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.